Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTR LadRx		$0.09	$0.05 ▼ $0.86	$4.14M	N/A	99,706 shs	4,000 shs
LIFE aTyr Pharma	$1.62 +1.9%	$1.85	$1.08 ▼ $2.70	$110.06M	1.25	519,419 shs	276,007 shs
OTLK Outlook Therapeutics	$8.29 -3.7%	$8.62	$4.00 ▼ $40.60	$107.85M	0.04	550,751 shs	234,500 shs
VICL Vical		$1.24	$0.60 ▼ $1.47	$21.01M	0.32	1.44 million shs	35,024 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTR LadRx	0.00%	0.00%	0.00%	0.00%	0.00%
LIFE aTyr Pharma	-1.24%	-10.17%	-18.67%	+11.97%	-17.19%
OTLK Outlook Therapeutics	-1.60%	-4.23%	+10.60%	+20.49%	-60.50%
VICL Vical	0.00%	0.00%	0.00%	0.00%	+46.06%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTR LadRx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LIFE aTyr Pharma	1.9329 of 5 stars	3.4	3.0	0.0	0.0	3.2	1.7	0.0
OTLK Outlook Therapeutics	3.0128 of 5 stars	4.4	2.0	0.0	0.0	3.0	1.7	0.6
VICL Vical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTR LadRx	N/A	N/A	N/A	N/A
LIFE aTyr Pharma	2.75	Moderate Buy	$23.67	1,360.91% Upside
OTLK Outlook Therapeutics	2.88	Moderate Buy	$46.43	460.01% Upside
VICL Vical	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest OTLK, CYTR, VICL, and LIFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/27/2024	OTLK Outlook Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
3/25/2024	OTLK Outlook Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00
3/15/2024	LIFE aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
3/15/2024	LIFE aTyr Pharma	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $16.00
2/21/2024	LIFE aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
2/16/2024	OTLK Outlook Therapeutics	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
2/15/2024	OTLK Outlook Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$60.00
1/25/2024	OTLK Outlook Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$31.40
1/25/2024	OTLK Outlook Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$40.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTR LadRx	N/A	N/A	N/A	N/A	N/A	N/A
LIFE aTyr Pharma	$350K	314.47	N/A	N/A	$1.54 per share	1.05
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.11) per share	N/A
VICL Vical	$1.62M	0.00	N/A	N/A	$1.82 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTR LadRx	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
LIFE aTyr Pharma	-$50.39M	-$0.96	N/A	N/A	N/A	N/A	-49.84%	-39.12%	5/14/2024 (Estimated)
OTLK Outlook Therapeutics	-$58.98M	-$4.00	N/A	N/A	N/A	N/A	-3,741.39%	-132.37%	5/20/2024 (Estimated)
VICL Vical	-$16.25M	-$0.81	N/A	N/A	N/A	-1,002.10%	-29.46%	-27.85%	N/A

Latest OTLK, CYTR, VICL, and LIFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/14/2024	Q4 2023	LIFE aTyr Pharma	-$0.23	-$0.25	-$0.02	-$0.25	N/A	N/A
2/14/2024	Q1 2024	OTLK Outlook Therapeutics	-$1.00	-$0.80	+$0.20	-$0.04	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTR LadRx	N/A	N/A	N/A	N/A	N/A
LIFE aTyr Pharma	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A
VICL Vical	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTR LadRx	N/A	N/A	N/A
LIFE aTyr Pharma	0.02	6.27	6.27
OTLK Outlook Therapeutics	N/A	0.44	0.44
VICL Vical	N/A	36.84	36.84

Ownership

Institutional Ownership

Company	Institutional Ownership
CYTR LadRx	N/A
LIFE aTyr Pharma	61.72%
OTLK Outlook Therapeutics	11.20%
VICL Vical	29.06%

Insider Ownership

Company	Insider Ownership
CYTR LadRx	N/A
LIFE aTyr Pharma	3.70%
OTLK Outlook Therapeutics	5.30%
VICL Vical	4.58%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTR LadRx	N/A	45.04 million	N/A	Not Optionable
LIFE aTyr Pharma	56	67.94 million	65.43 million	Optionable
OTLK Outlook Therapeutics	24	13.01 million	12.32 million	Optionable
VICL Vical	30	22.84 million	N/A	Not Optionable

OTLK, CYTR, VICL, and LIFE Headlines

Source	Headline
	Evan Gershkovich’s sister was the quiet one. Now she’s his voice. msn.com - March 29 at 9:52 AM
	Video: Travis Kelce’s Friends Attempt to Distract Him in Golf by Playing Taylor Swift’s Song ijr.com - March 29 at 9:52 AM
	Song Suffragettes celebrates 10 years with Wynonna, female country chart-toppers, more msn.com - March 29 at 9:52 AM
	Song lyrics getting simpler, more repetitive, angry and self-obsessed – study theguardian.com - March 29 at 9:52 AM
	Beyoncé’s Younger Daughter Rumi Carter Joins Her on New Song ‘Protector’ msn.com - March 29 at 2:11 AM
	Beyoncé features Shaboozey on her song 'Spaghettii': Who is the hip-hop, country artist? msn.com - March 29 at 2:11 AM
	Creed frontman Scott Stapp on singing his 'life story,' moving to Nashville and finding a dream team msn.com - March 28 at 9:10 PM
	BBC stands by replacing singer with AI-generated voice msn.com - March 28 at 9:10 PM
	Song Lyrics Really Are Getting Simpler and More Repetitive, Study Finds scientificamerican.com - March 28 at 9:10 PM
	Funniest misheard Beyoncé lyrics, from 'Singing lettuce' to 'No bottom knee' msn.com - March 28 at 9:10 PM
	Kanye wife Bianca Censori’s voice heard for first time in newly resurfaced video nydailynews.com - March 28 at 4:10 PM
	Top 'American Idol' and 'The Voice' contestants come from these states: Where Tennessee ranks in the list tennessean.com - March 28 at 4:10 PM
	Song Lyrics Are Now More Repetitive and Simple, Study Confirms msn.com - March 28 at 4:10 PM
	KJP Declares Press Gaggle off the Record as Obama’s Voice Is Heard ijr.com - March 28 at 4:10 PM
	Song lyrics have become angrier since the 80s, study shows msn.com - March 28 at 4:10 PM
	Boston Red Sox minor league pitcher, former Navy standout Noah Song set to undergo Tommy John surgery baltimoresun.com - March 28 at 4:10 PM
	Bachelor Joey Graziadei Reveals the Taylor Swift Song That Reminds Him of New Fiancée Kelsey Anderson msn.com - March 28 at 4:10 PM
	Song Lyrics Are Getting Simpler, More Repetitive: Study barrons.com - March 28 at 4:10 PM
	‘Past Lives’ director Celine Song delivers Pan Asian American Heritage Month keynote speech yaledailynews.com - March 28 at 11:10 AM
	Vampire Weekend Share Video for New Song “Mary Boone”: Watch yahoo.com - March 28 at 11:10 AM
	Fans freak hearing Kanye West’s wife Bianca Censori’s voice for first time in old video msn.com - March 28 at 11:10 AM
	Beyoncé's ‘Cowboy Carter’ tracklist is a puzzle. What we've deciphered so far msn.com - March 28 at 11:10 AM
	Kate Hudson celebrates motherhood in new song 'Live Forever' upi.com - March 28 at 11:10 AM
	This song is our story foxnews.com - March 28 at 11:10 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

LadRx

NASDAQ:CYTR

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

aTyr Pharma

NASDAQ:LIFE

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Outlook Therapeutics

NASDAQ:OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Vical

NASDAQ:VICL

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial